However, Phase II clinical trials in which patients with relapsing-remitting MS were administered Lenercept, a sTNF-RI fusion protein that neutralizes TNF-α were halted when disease acutely worsened [21]. This evidence concerns the gene TNF and relapsing-remitting multiple sclerosis.